Some types of prostate cancer may not be as aggressive as originally thought – Mirage News

UCLA

Dr. Amar Kishan

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group known as Gleason grade group 5 and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.

One subtype, which accounts for about 15% of the grade group 5 cancers, has highly aggressive features and is associated with much worse outcomes than the other subtypes. Another, which makes up about 20% of the tumors, appears to be much less aggressive and may not require intensified and aggressive treatments. Traditionally, all tumors in Gleason grade group 5 have been treated in the same way.

BACKGROUND

Prostate cancer is the leading solid-tumor cancer among men in the United States and a major cause of morbidity globally. While early-stage, localized prostate cancer is curable, current treatments dont always work for everyone. To find out why standard treatment may work for some and not others, the UCLA researchers looked at tumors in the Gleason grade group 5 subset of prostate cancer. These tumors are at the highest risk to fail standard treatment, leading to metastasis and death. The researchers thought that studying the gene expression the unique signature of each cancer cell in these tumors might provide insight into how to make treatments more personalized for each patient.

METHOD

The researchers first analyzed data from more than 2,100 Gleason grade group 5 tumors, looking at how the genetic blueprints differed among the tumors. They identified distinct clusters of subgroups and validated their findings by analyzing an additional cohort of more than 1,900 Gleason grade group 5 prostate cancers.

IMPACT

By using the genetic information from tumors in men with prostate cancer, physicians hope to one day create more personalized treatments based on the actual characteristics of the cancer. This information will help optimize quality of life and avoid overtreating subgroups of men who may not need aggressive treatments.

AUTHORS

The studys lead author is Dr. Amar Kishan, an assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center. The co-senior authors are Dr. Joanne Weidhaas, a professor of radiation oncology and director of translational research at the Geffen School of Medicine, and Paul Boutros, a professor of urology and human genetics and director of cancer data science for the Jonsson Cancer Center. Boutros is also a member of the UCLA Institute of Urologic Oncology and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Other UCLA authors include David Elashoff, Dr. Rob Reiter and Dr. Matthew Rettig.

JOURNAL

The study was published in the journal European Urology.

FUNDING

The research was funded in part by an award from the American Society for Radiation Oncology and the Prostate Cancer Foundation, the Radiological Society of North America, and the National Institutes of Health.

Link:
Some types of prostate cancer may not be as aggressive as originally thought - Mirage News

Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2019 To 2025 – Cole of Duty

The Stem Cell Therapy Market report has been evaluated with respect to vital aspects such as Industry Strategies, Evolving Technology, Growth rate, Key Companies, Business Competitors, and Forecast till 2025. Substantial details highlighting the importance of the most significant sectors of this business are included in the study.

The Stem Cell Therapy Market is anticipated to record its name in the billion-dollar space within seven years, by exceeding revenue of US$ 15 billion by 2025, with an anticipated CAGR of 10.2% through 2025.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/3331

The Stem Cell Therapy Market report delivers a concise analysis pertaining to the competitive landscape of this industry. All the vital information with regards to this parameter have been covered in the report in a systematic manner. The overall summary has been included after conducting a detailed analysis of the driving parameters, the factors that may hamper the market growth, as well as the growth prospects that this business space has in the future.

Market Segmentation:

Know about Market growth in New Research and its Top growing factors by Key Companies like

Astellas Pharma Inc, Capricor Therapeutics, Cellectis, Cellular Dynamics, Celyad, CESCA Therapeutic, DiscGenics, Gamida Cell, Mesoblast Ltd, Novadip Biosciences, OxStem, ReNeuron Group plc, Takeda Pharmaceuticals

Comprehensive Review of Market Growth, Applications, and Future Prospects

The Regional Evaluation Ensures

Make an inquiry for purchasing this [emailprotected] https://www.gminsights.com/inquiry-before-buying/3331

The Stem Cell Therapy Market research report presents a detailed outline of Stem Cell Therapy Market this is mainly inclusive of the generic market definitions, the numerous segmentations, as well as the application landscape. The report outlines a detailed examination of the industry vendors from a regional and global perspective.

An exhaustive brief of the various forecast trends and demand till the year 2025 has been given in the report. The study is inclusive of information pertaining to the numerous firms that form a part of the competitive terrain of this business sphere. Also, the report contains, in exclusive detail, information on the many innovations in this sector, technologies adopted, and also many other factors impacting the product demand.

Report Growth Drivers

Request for discount @ https://www.gminsights.com/request-discount/3331

The Stem Cell Therapy Market Report Includes

Read the original post:
Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2019 To 2025 - Cole of Duty

(2020-2026) Stem Cell Manufacturing Market Research, Growth Opportunities, Analysis and Forecasts Report | Thermo Fisher Scientific, Merck Group),…

Stem Cell Manufacturing Industry Amid Global COVID-19 (Coronavirus) Crisis: Report Hive Viewpoint

The Stem Cell Manufacturing market report [6 Years Forecast 2020-2026] focuses on the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. The intelligence report prepared contains details on the leading players of the Global Stem Cell Manufacturing Market, along with various depending aspects related and associated with the market. Profile the Top Key Players of Stem Cell Manufacturing, with sales, revenue and global market share of Stem Cell Manufacturing are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Stem Cell Manufacturing market business development trends and selling channels square measure analyzed. Stem Cell Manufacturing industry research report enriched on worldwide competition by topmost prime manufactures which providing information such as Company Profiles, Gross, Gross Margin, Capacity, Product Picture and Specification, Production, Price, Cost, Revenue and contact information.

The Stem Cell Manufacturing industry profile also contains descriptions of the leading topmost manufactures/players like (Thermo Fisher Scientific (US), Merck Group (Germany), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Miltenyi Biotec (Germany), Takara Bio Group (Japan), STEMCELL Technologies (Canada), Pharmicell (South Korea), Osiris Therapeutics (US), Anterogen (South Korea), Cellular Dynamics International (US), MEDIPOST (South Korea), Lonza Group (Switzerland), Holostem Terapie Avanzate (Italy), Pluristem Therapeutics (Israel)) which including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments. COVID-19 can affect the global economy in three main ways: by directly affecting Production and Demand, By Creating Supply Chain and Stem Cell Manufacturing Market Disruption, and by its financial impact on firms and financial markets.

>>> To know How COVID-19 Pandemic Will Impact This Market/Industry | Request a sample copy of the Stem Cell Manufacturing Market report:

The report additionally reviews the market key drivers, restraints, growth signs, challenges, market dynamics, aggressive landscape, and different key aspects related to the global Stem Cell Manufacturing market. The report presents a top to bottom illumination of the markets past, current, and future status. It offers an analysis of emerging market sectors and development opportunities in the market. Market structure is described by analyzing the segments such as product type, application, end-users, key regions, and key companies. Further, the report gives in detailed information about the players on the basis of type, financial position, price, growth strategies, product portfolio, and regional presence of the players in the market.

Vital data enclosed in the report:

Product development and innovations relevant to the Stem Cell Manufacturing market Region and country-wise assessment of the different segments and sub-segments of the Stem Cell Manufacturing market and the COVID-19 pandemic impact on each segment Investment scenario in different regional markets post in the current market landscape Pricing strategies and structure adopted by various players in the Stem Cell Manufacturing market Raw material suppliers, vendors, and manufacturers in the Stem Cell Manufacturing market

The scope of the Report:

The report segments the global Stem Cell Manufacturing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Stem Cell Manufacturing market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

The report includes a detailed segmentation study of the global Stem Cell Manufacturing market, where all of the segments are analyzed in terms of market growth, share, growth rate, and other vital factors. It also provides the attractiveness index of segments so that players can be informed about lucrative revenue pockets of the global Stem Cell Manufacturing market. The extensive evaluation of segments provided in the report will help you to direct your investments, strategies, and teams to focus on the right areas of the global Stem Cell Manufacturing market.

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate for each application.

HSCs, MSCs, iPSCs, ESCs, Instruments, Media, Consumables

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Research, Target Identification, Therapy (Autologous, Allogeneic), Cell Banks

Regional Spectrum:

Research contains regional segmentation which describes the regional aspects of the global Stem Cell Manufacturing market. It explains the framework that is expected to affect the entire market. It covers the scenario of the market and anticipates its impact on the market. Main region market conditions are assessed with respect to the product price, profit, capacity, production, supply, demand, and market growth rate and forecast, etc.

Market Size Segmentation by Region & Countries (Customizable):

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Our exploration specialists acutely ascertain the significant aspects of the global Stem Cell Manufacturing market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Stem Cell Manufacturing market situation. In this Stem Cell Manufacturing report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Stem Cell Manufacturing report comprises of primary and secondary data which is exemplified in the form of pie outlines, Stem Cell Manufacturing tables, analytical figures, and reference diagrams. The Stem Cell Manufacturing report is presented in an efficient way that involves basic dialect, basic Stem Cell Manufacturing outline, agreements, and certain facts as per solace and comprehension.

Important Features that are under offering & key highlights of the report:

Detailed overview of Stem Cell Manufacturing market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Stem Cell Manufacturing market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards Stem Cell Manufacturing market performance Market players information to sustain and enhance their footprint

>>> To get Incredible Discounts on this Premium Report, Click Here @ https://www.reporthive.com/2288512/check_discount

Table of Content

1 Introduction 9

1.1 Industry Definition and Research Scope 91.1.1 Industry Definition 91.1.2 Research Scope 101.2 Research Methodology 131.2.1 Overview of Market Research Methodology 131.2.2 Market Assumption 141.2.3 Secondary Data 141.2.4 Primary Data 141.2.5 Data Filtration and Model Design 161.2.6 Market Size/Share Estimation 171.2.7 Research Limitations 181.3 Executive Summary 19

2 Market Overview and Dynamics 21

2.1 Market Size and Forecast 212.2 Major Growth Drivers 222.3 Market Restraints and Challenges 272.4 Emerging Opportunities and Market Trends 302.5 Porters Fiver Forces Analysis 34

3 Segmentation of Global Market by Offering 38

3.1 Market Overview by Offering 383.2 Software 403.3 Service 493.3.1 Professional Services 513.3.2 Managed Services 52

4 Segmentation of Global Market by Application 53

4.1 Market Overview by Application 534.2 Research, Target Identification, Therapy (Autologous, Allogeneic), Cell Banks

5 Segmentation of Global Market by Deployment 61

5.1 Market Overview by Deployment 61

6 Segmentation of Global Market by Industrial Vertical 66

6.1 Market Overview by Industrial Vertical 66

7 Segmentation of Global Market by End User 77

7.1 Market Overview by End User 777.2 HSCs, MSCs, iPSCs, ESCs, Instruments, Media, Consumables

8 Segmentation of Global Market by Region 82

8.1 Geographic Market Overview 2019-2030 828.2 North America Market 2019-2030 by Country 868.2.1 Overview of North America Market 868.2.2 U.S. 908.2.3 Canada 948.2.4 Mexico 968.3 European Market 2019-2030 by Country 988.3.1 Overview of European Market 988.3.2 Germany 1028.3.3 UK 1048.3.4 France 1068.3.5 Spain 1088.3.6 Italy 1108.3.7 Russia 1128.3.8 Rest of European Market 1148.4 Asia-Pacific Market 2019-2030 by Country 1168.4.1 Overview of Asia-Pacific Market 1168.4.2 Japan 1208.4.3 China 1238.4.4 Australia 1258.4.5 India 1278.4.6 South Korea 1298.4.7 Rest of APAC Region 1318.5 South America Market 2019-2030 by Country 1338.5.1 Argentina 1368.5.2 Brazil 1388.5.3 Chile 1408.5.4 Rest of South America Market 1428.6 Rest of World Market 2019-2030 by Country 1438.6.1 UAE 1468.6.2 Saudi Arabia 1488.6.3 South Africa 1508.6.4 Other National Markets 152

9 Competitive Landscape 153

9.1 Overview of Key Vendors 1539.2 New Product Launch, Partnership, Investment, and M&A 1569.3 Company Profiles 158Thermo Fisher Scientific (US), Merck Group (Germany), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Miltenyi Biotec (Germany), Takara Bio Group (Japan), STEMCELL Technologies (Canada), Pharmicell (South Korea), Osiris Therapeutics (US), Anterogen (South Korea), Cellular Dynamics International (US), MEDIPOST (South Korea), Lonza Group (Switzerland), Holostem Terapie Avanzate (Italy), Pluristem Therapeutics (Israel)

10 Investing in Global Market: Risk Assessment and Management 177

10.1 Risk Evaluation of Global Market 17710.2 Critical Success Factors (CSFs) 180

Related Reports and Products 183

>>> Make an enquiry before buying this report @ https://www.reporthive.com/2288512/enquiry_before_purchase

Why Report Hive Research:

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc.

Contact Us:

Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: https://www.reporthive.comEmail: [emailprotected]Phone: +1 312-604-7084

Read the original here:
(2020-2026) Stem Cell Manufacturing Market Research, Growth Opportunities, Analysis and Forecasts Report | Thermo Fisher Scientific, Merck Group),...

GC027 Shows Promise as Therapy for Adult Relapsed, Refractory T-Cell ALL – Hematology Advisor

GC027,the first humanized chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractoryT-cell acute lymphoblastic leukemia (T-ALL) in adults, appears to be botheffective and have a manageable safety profile, according to research presentedduring the ASCO20 Virtual Scientific Program.

Mortalityrates are high in relapsed/refractory T-ALL, necessitating novel treatments toimprove survival. CD7, a T-cell antigen expressed in more than 95% of diseasesamples, represents a plausible target in this setting. GC027, which targetsCD7 and was developed using using lentivirus and CRISPR/Cas9, showed promise inmurine models for treating T-ALL.

For this single-arm, open-label study, researchers evaluated the safety and efficacy of GC027 in relapsed/refractory T-ALL. All included patients were between 18 and 70 years old, had a projected survival of more than 3 months, and had a performance status of 0 to 2. Patients with extramedullary disease or central nervous system involvement were not eligible to participate.

Fivemen (median age, 24 years) were enrolled in the trial. The median number ofprior lines of therapy was 5, no patients had undergone prior stem celltransplantation, and the median baseline bone marrow tumor burden was 38.2%.

All5 patients had a complete response or complete response with incomplete hematologicrecovery, and 4 of the 5 patients were minimal residual diseasenegative.

Allpatients also experienced grade 3 (4 patients) or 4 (1 patients) cytokinerelease syndrome; no grade 5 events of any kind were reported.

Witha single infusion of GC027, 80% of the patients had robust CAR-T cell expansionand achieved persistent [minimal residual diseasenegative complete response]without using any biologics as part of the preconditioning therapy or bridgingto [hematopoietic stem cell transplantation], the authors wrote.

Wang X, Li S, Gao L, et al. Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl): abstr 3013.

Read the rest here:
GC027 Shows Promise as Therapy for Adult Relapsed, Refractory T-Cell ALL - Hematology Advisor

Early Palliative Care Reduces Anxiety and Depression in Acute Myeloid Leukemia Treatment – Cancer Health Treatment News

Acute myeloid leukemia (AML) often comes on abruptly and is commonly treated with an intensive course of chemotherapy that requires hospitalization for four to six weeks. As with stem cell (bone marrow) transplantation, which entails a similar extended hospitalization, the treatment can cause severe physical and psychological symptoms that can persist for months or years.

With stem cell transplantation, however, one intervention has been shown to improve quality of life: the early introduction of palliative care, evidence-based medical care focused on improving quality of life for people with serious illness. Often confused with end-of-life or hospice care, palliative care can benefit people at any stage of cancer who are facing serious side effects.

Now, according to a study presented at the American Society of Clinical Oncology 2020 virtual meeting, palliative care can greatly benefit people with AMLwhen its introduced at the very beginning of treatment.

In the multi-site randomized trial, 160 people with AML were assigned either to usual care (74) or usual care plus palliative care (86). They were all high-risk AML patients, meaning they were over 60 years old, had an existing blood disorder or had already been treated for AML and it had reoccurred. Those in the palliative care group saw palliative care clinicians at least twice a week throughout their initial hospitalization and during any further rehospitalizations. The study subjects completed several assessments of their symptoms and psychological status over six months.

The palliative care clinicians helped them address physical symptoms, including pain, nausea, fatigue, diarrhea, constipation and insomnia, as well as psychological symptoms, such as anxiety, depression and posttraumatic stress disorder (PTSD). For those who had subsequent hospitalizations, many of whom were facing end-of-life situations, the palliative care team also addressed understanding their illness, identifying individual goals and expectations, making treatment decisions and advanced-care planning.

Those who received palliative care reported better overall quality of life, a lower level of symptom burden, less depression, less anxiety and fewer PTSD symptoms by the end of the second week of treatment. The improvements were sustained over the next six months. The intervention led to a significant improvement in quality of life compared to usual care [and] significant improvement in anxiety symptoms, depression symptoms, as well as PTSD symptoms at week 2, said lead study author Areej El-Jawahri, MD, an oncologist at Brigham and Womens Hospital in Boston.

The palliative care intervention was also associated with a beneficial change in those patients who eventually diedless aggressive interventions at the very end of life. These interventions sometimes cause suffering without extending the quality or quantity of life. In the study, those in the palliative care group were more likely to discuss their end-of-life care wishes with their clinicians and less likely to receive chemotherapy in the last 30 days of life.

Oncologists rarely consultant palliative care for patients with AML, said El-Jawahri, who hopes this study will begin to change that fact. Her conclusion: Palliative care should be considered a new standard of care for patients with AML.

To read the abstract, click here.

To learn more about palliative care, see The New Palliative Care.

Go here to see the original:
Early Palliative Care Reduces Anxiety and Depression in Acute Myeloid Leukemia Treatment - Cancer Health Treatment News

ReNeuron encouraged by progress in stroke and RP treatments – Proactive Investors Australia

What the company does

Human retinal progenitor cells (hRPC)

Human retinal progenitor cells differentiate into components of the retina.

Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.

The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP).

CTX Cells

CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke.

Reneurons product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments.

Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.

Exosome platform

Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that arebelieved to play a key role in cell-to-cell communication.

ExoPr0, Reneurons first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle

hRPC

's ()human retinal progenitor cells (hRPC) have scored some early success.

A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment.

Six months after treatment there was a mean improvement of 18.5per treated eye, with a mean improvement of 12 letters per treated eye after nine months, whereasinexorable disease progression is the norm for this disease.

With a total of 22 patients now treated and the study still ongoing, ReNeuron said the efficacy in subsequent patients was seen but at a lower rate and magnitude, with improvement in visual acuity ranging from +5 to +11 letters in the treated eye threemonths after treatment.

In February, clinicaldata from the PISCES II clinical trial were published in peer-reviewedJournal of Neurology, Neurosurgery, and Psychiatry.

CTX

A peer journal review published in May indicated a CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

ReNeuron has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can cause functional and behavioural recovery in animal models of ischemic (restriction of blood supply) injury.

The new data showed that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.

Coronavirus

In April, Reneuron said it haddeveloped a line of the human exosomes that can deliver a medically relevant payload: Viral vaccines thatmight help in the fight against coronavirus.

The stem cell specialist added that the disruption from lockdowns would inevitably lead to delays in the recruitment of patients for trials of its treatments for stroke disability and retinitis pigmentosa (RP).

It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.

See original here:
ReNeuron encouraged by progress in stroke and RP treatments - Proactive Investors Australia

Alternative and Complementary Treatments for Cancer – HealthCentral.com

On this page:BasicsComplementary TreatmentAlternative Treatment EffectivenessSide EffectsCancer Cure ScansDiet and Exercise

Youve seen the headlines about natural medicine trends, from yoga to supplements to diet and exercise fads. When it comes to cancer, you want to know what will help you safely regain your health during treatment and after. But there are loads of competing, sometimes-confusing info to sift through. What can you trust? Well, you can start with us here at HealthCentral: We went to the experts to learn all the science-based truth on complementary care for cancer.

First, lets clarify how cancer comes to be: Cancer occurs when abnormal cells anywhere in your body grow out of control, due to mutations in their DNA. Normal cells divide, age and die predictably, copying DNA as they go. Cancer cells, however, dont follow those rules. Rather than die off, they mutate, replicate, and form tumors.

Whats known as the primary site of your cancer is the spot where these cells start growing, and that organ or area determines the type of cancer you have. When cancerous cells journey through your blood or lymphatic system (the network of tissues and organs that flush out toxins, waste, and other undesirables), the areas they invade are metastatic sites.

Note that a cell can be abnormal without being cancerous (also known as malignant). It could be benign (not cancer), or precancerous or premalignant (likely to become cancer). Through screening and testing, docs can determine exactly what youre dealing with.

That depends on what kind of cancer you have, what stage its in, and other factors. Treatment can include:

Doctors often try more than one treatment, spaced out over weeks and months, as they gauge how your body responds. Your doc might even start you on multiple treatments at the same time.

Youve probably heard of complementary care. Or maybe you know it as alternative care. You know a bit of what these treatments might include (youre thinking meditation, herbs, and maybe yoga?). But did you know that while complementary and alternative care are often lumped together (as CAM, Complementary and Alternative Medicine), theyre not the same?

Complementary medicine is used in addition to conventional cancer care. It can include products, practices, and healthcare systems outside of mainstream medicine. These methods dont cure cancer, but work in conjunction with conventional cancer treatments to help in a variety of ways, including pain management and emotional support. Many complementary medicine practices can be considered evidence-based medicine (scientifically studied in randomized controlled trials, the highest level of evidence that guides cancer care).

When complementary medicine works harmoniously with conventional medicine, its an approach known as integrative medicine, or integrated care, where physicians treat you holisticallymeaning caring for you as a whole patient, taking into account all facets of your cancer experience. These can include:

When integrative medicine is administered to treat cancer, its known as integrative oncology, a patient-centered, evidence-informed field of cancer care. It may include:

Alternative medicine, in contrast, is used in place of conventional medicine. Rather than going hand-in-hand with, say surgery and chemo, alternative medicine is done instead of those evidence-based cancer treatments.

A quick note: before you try any new approach during (and after) your cancer treatment journey, make sure to discuss it with your doctor.

If youve used or are considering using complementary medicine as a cancer patient, youre not alonea national survey found that 65% of respondents whod been diagnosed with cancer had used some form of it.

Theres good reason to explore complementary care if you have cancer. It can be part of your supportive carehelping where you need it, like soothing and calming your mind and body as you go through this challenging time. Indeed, research suggests that complementary medicine can assist by:

There are easily hundreds of complementary treatments for cancer, so weve selected a small sample to discuss here. Possibilities include:

Acupuncture: Theres substantial evidence that this ancient Chinese practice of using sterile needles to stimulate different areas of the body can help manage cancer treatment-related nausea and vomiting. It may also help relieve cancer pain and other symptoms, but theres not enough evidence yet to support that.

Herbs: Ginger, for instance, has been shown to help control nausea from chemotherapy when used with conventional anti-nausea medications. Just keep in mind that any supplements you consume can change your body physiologicallynothing you ingest is without the potential for adverse effects. For instance, herbs can impact blood sugar levels and the bloods ability to clot.

Massage therapy: Sure, it feels sublime, and it turns out to have additional benefits too: research suggests that massage therapy can help relieve some cancer symptoms including:

Just be careful not to have deep tissue massage near surgery sites, tumors, or any medical devices. And always tell your therapist about your cancer diagnosis.

Meditation: Mindfulness-based meditation has been shown to improve quality of life during treatment. How? Studies of cancer patients have revealed the following happiness-boosting benefits:

Supplements: Herbal supplements for cancer could potentially help manage side effects like nausea and vomiting, pain, and fatigue, but more scientific evidence is required to make safe decisions about the use of these supplements.

Yoga: Preliminary data of this ancient mind/body practice from India suggests that those who do yoga could see improvements in these areas:

Another benefit: It might help lessen fatigue in breast cancer patients and survivors. More study into the myriad benefits of yoga is needed.

Other approaches: These include hypnosis, relaxation therapy, and biofeedback, all of which might help manage cancer symptoms and treatment side effects, based on study results.

One thing to note about all of these approaches: they might not be covered by your health insurance. According to the American Cancer Society, major insurers, including Blue Cross and Medicare, are starting to cover some complementary treatments. On the list above, acupuncture is most commonly covered. Contact your insurer to see what complementary treatments, if any, are paid for. They might be able to direct you to local providers who are covered under your plan.

When the treatments we discussed earlier (and the hundreds of others that are offered) are used in place of conventional medicine, its known as an alternative treatment. Nearly 40%, or 4 out of 10 Americans, believes that cancer can be cured by alternative treatments, a 2018 survey of cancer patients and people without cancer, found. However, while research shows that complementary medicine can play an important role in conventional cancer medicine, the same hasnt been readily found for alternative treatment.

Case in point: in 2009, the Society for Integrative Oncology (the leading international organization for healthcare professionals and researchers working in the field of complementary therapies in cancer care) published guidelines for healthcare professionals when using complementary medicine.

The org reminded healthcare professionals and patients that unproven cancer treatment methods shouldnt be used in place of conventional options because delaying cancer treatment thats evidence-based and shown to work reduces the chance of remission/cure for cancer patients.

Its important to talk with your healthcare professionals about the risks of using alternative therapies so you can make an informed decision about whats best for your health.

There are definite side effects with CAM. You might think that because something is natural, its safe. But this isnt always the case. Arsenic is natural, for instance, but you wouldnt want to start taking it in large doses.

Another example: Chemotherapy has a multitude of side effects because it destroys both cancerous cells and healthy cells. Its been cited by many as harmful because its made from chemicals. But did you know, some forms of chemo come from nature? Three drugs (Vincristine, Vinblastine, and Vinorelbine) are derived from plant alkaloids and are made from the periwinkle plant (Catharanthus Rosea). Chemo drugs called taxanes (Paclitaxel and Docetaxel) come from the bark of the Pacific Yew tree (Taxus).

Know too that just because something is sold, doesnt mean its been vetted or approved for usefor safety or qualityby the U.S. Food and Drug Administration (FDA). The FDA doesnt regulate vitamins and supplements, so the onus is on us to do our best to source safe, trustworthy products.

Its vital to tell your cancer healthcare team about every treatment and therapy youre using for your cancer, whether its receiving acupuncture for nausea, going to the chiropractor for pain, adding St. Johns Wort to your supplement regime to help manage depression, or getting a massage to feel better.

If youre reluctant to be open with your doc, youre not alone: 29% of cancer patients did not disclose their CAM practices to their providers, according to one study. Secret-keeping could be downright dangerous. Lets use these four seemingly innocuous examples to illustrate why:

Being open with your doc--both before you start a complementary treatment and while youre on it--is key to helping it complement, rather than detract, from the conventional care youre receiving.

When you have cancer, you of course want a cure (as quickly and painlessly as possible, please). But that desire can leave you vulnerable to fake claims, especially in the alternative medicine space. Both the FDA and the Federal Trade Commission (FTC) regularly warn the public about fraudulent cancer treatments.

It can be hard to spot the signs of snake oil. Without a medical degree, how can you be wise to empty promises? Youll often see the same language used in cancer CAM scams, according to the FDA. These phrases should raise a red flag that a treatment is just too good to be true:

Heres how you can protect yourself while receiving evidence-based integrated care:

You might be wondering now: with all this talk of complementary and alternative medicine, what about food? And diet? And exercise? What role does it play in all this? Is there a cancer diet that could be a complementary treatment?

Turns out, theres a strong body of evidence that a healthy diet and regular physical activity are associated with a reduced risk of cancer. The scientific literature links nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. Even after a cancer diagnosis, by making smart choices about what they put on their plate, patients can:

Food has power. To wield it, the American Institute for Cancer Research and American Cancer Society recommends you:

As for physical activity? While you should talk to your healthcare team about what kind and amount of exercise is safe during treatment, The American College of Sports Medicine (ACSM) has issued guidelines for physical activity for cancer survivors, suggesting 150-300 minutes per week of moderate to vigorous physical activity. Exercise is a real magic pill, helping to:

As you can imagine, all of these benefits that come along with being active are particularly important when youre trying to put cancer behind you. Resistance training, in particular, has been proven to improve:

Exercise, like so many CAM options, can help you both feel stronger and respond to treatment better. Just as with other types of complementary treatments, youll want to talk to your doc about how to integrate it, so you can reap the maximum benefits both from your lifestyle changes and your conventional cancer treatment.

Researchers have found that a healthy diet is associated with a reduced risk of cancer. Even if you have cancer, it can help lessen the impact of side effects and improve your quality of life. Studies link nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. All to say that food matters.

Heres the thing: there are therapies that can help you go into remission (the period when your signs and symptoms of cancer are reduced). And some healthcare professionals consider cancer cured if it hasnt returned after five years (also called complete remission). Treatments that achieve a complete remission/cure can include therapies that come from a natural source, like some forms of chemo, which are derived from plant alkaloids. But anyone promising a natural cure for cancer that doesnt have evidence to back up that claim is likely pedaling bunk.

As weve discussed, herbs can be excellent complementary treatment in oncology for things like nausea, but any claim of curing cancer should be tempered by evidence-based medicine results (meaning, proof to back up those claims).

The American Academy of Dermatology warns that black salve isnt as safe as you might think, stating that it has never been proven to work. An article on the AADs website cites reports of bad outcomes for people who tried to treat their cancer (including melanoma) using black salve. The U.S. Food and Drug Administration (FDA) warns against products that are touted as cures for cancer without evidence: The FDA urges consumers to steer clear of these potentially unsafe and unproven products and to always discuss cancer treatment options with their licensed health care provider.

Link:
Alternative and Complementary Treatments for Cancer - HealthCentral.com

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -…

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Wei Li as acting Chief Scientific Officer (CSO), effective June 1, 2020.

During her biotech career, Dr. Li co-founded two companies and built up extensive expertise in all aspects of drug research and development, including preclinical development and pharmacology, clinical development and operations, regulatory affairs, biomarker development and biomanufacturing.

Most recently, Dr. Li was Chief Development Officer at OliX Pharmaceuticals, a leading public South Korean biotech company developing siRNA therapeutics for multiple indications. She also served as Executive Vice President, Product Development at Boston Biomedical, Inc (BBI) from 2007-2018, playing a key role in growing it from a start-up in 2007 to an industry leader in cancer stem cell research, including through the acquisition by Sumitomo Dainippon in 2012. Dr. Li led the development of napabucasin (BBI608), a first-in-class drug selected as one of the worlds top ten cancer drugs in late stage clinical development by Fierce Biotech. Dr. Li started her career at ArQule, a public biotech company developing targeted therapies for hematological malignancies and acquired by Merck &Co in 2019.

Wei Li holds a PhD in Molecular Virology from Georgia State University and completed her Postdoctoral Training at Harvard Medical School.

Dr. Wei Li said: I am thrilled to be joining the great team of scientists and entrepreneurs at Cytovia Therapeutics. NK-cell based therapeutics are at an inflection point. Initial clinical trials have shown promising safety and efficacy. Off-the-shelf manufacturing promises broader and faster patient access. Cytovia Therapeutics has an excellent iPSC CAR-NK platform and a strong pipeline in both hematological and solid tumors. It is tremendously exciting to be involved in this stage of the companys development.

Dr Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc said: We are delighted to welcome Dr. Wei Li to Cytovia Therapeutics as Chief Scientific Officer. Wei has a stellar track record of bringing innovative oncology drugs from discovery to clinical development. Her operational excellence and entrepreneurial drive will be critical to help bring multiple iPSC CAR NK therapeutics to initial clinical trials starting in 2021.

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more at http://www.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, IncSophie BadrVP corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Read the original:
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -...

Tiny Human Livers Grown in The Lab Have Been Successfully Transplanted Into Rats – ScienceAlert

Scientists have successfully transplanted functional miniature livers into rats, after growing the bioengineered organs in the lab from reprogrammed human skin cells.

The experiment, which gave the animals working liver organs, could lay the groundwork for future treatments to address terminal liver failure a disease that claims the lives of over 40,000 people in the US every year.

While there's still a lot of work to be done before the technique can directly aid human patients, the researchers say their proof of concept may help underpin a future alternative to liver transplants, which are often incredibly expensive procedures to perform, in addition to being strictly limited by donor supply.

Another positive outcome would be using the approach to temporarily augment failing liver function in patients, lengthening people's lives while they're on the waiting list for these vital organs: a situation facing about 14,000 Americans at any given moment, most of whom won't ever receive a transplant.

"The long-term goal is to create organs that can replace organ donation, but in the near future, I see this as a bridge to transplant," explains pathologist Alejandro Soto-Gutirrez from the University of Pittsburgh.

"For instance, in acute liver failure, you might just need hepatic boost for a while instead of a whole new liver."

To grow their mini livers, the researchers took human skin cells donated by volunteers and reverted them to a stem cell state, known as induced pluripotent stem cells, from which other kinds of cell types can be derived.

The researchers then induced differentiation in the cells with the aid of hormones and other chemicals, prompting them to become liver cells, which were cultured in the lab.

While it ordinarily takes two years for a human's liver to mature from the moment of their birth, the researchers were able to grow their miniature analogues in only a matter of weeks, seeding the grown cells on a rat liver scaffold that had been stripped of its rat cells.

While previous experimental liver graft research has incorporated rodent cells onto the scaffold, here the researchers used the human stem cells to populate the liver's functional tissue, along with its vascular system and bile duct network.

When transplanted into five rats, the mini livers appeared to be functional. After four days - at which point the animals were sacrificed and dissected - tests revealed that the bioengineered livers secreted bile acids and urea; human liver proteins in the animals' blood were another sign that the organs were working.

Not that the transplants functioned perfectly. Evidence of poor blood flow into the graft, in addition to thrombosis and ischemia, reveals there are still serious difficulties in properly connecting grafts like these to an animal's vascular network.

Nonetheless, it's still a remarkable achievement. For a short time, five rats lived their lives with miniature human livers, which isn't something that's ever been demonstrated before, and it could bring us closer to employing the same techniques for the benefit of human patients one day.

That day might be a long time away (perhaps a decade off, the researchers suggest), although it depends on a huge range of future experiments succeeding, including demonstrating that these kinds of engineered transplants are safe for humans, which remains to be seen.

In the meantime, methods like this including work pioneered by the same laboratory last year could enable the use of such mini organs to study simulated diseases and test different treatment options.

"I believe it's a very important step because we know it can be done," Soto-Gutirrez explained to Inverse. "You can make a whole organ that can be functional from one cell of the skin."

The findings are reported in Cell Reports.

View post:
Tiny Human Livers Grown in The Lab Have Been Successfully Transplanted Into Rats - ScienceAlert

Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts – Texas A&M University Today

NICE ink developed by Texas A&M researchers can be used to 3D print customizable craniofacial implants.

Courtesy of Akhilesh Gaharwar

Subtle variations in the architecture of the 22 bones of the skull give each one of us a unique facial profile. So repairing the shape of skull defects, in the event of a fracture or a congenital deformity, calls for a technique that can be tailored to an individuals face or head structure.

In a new study, researchers at Texas A&M University have combined 3D printing, biomaterial engineering and stem cell biology to create superior, personalized bone grafts. When implanted at the site of repair, the researchers said these grafts will not only facilitate bone cells to regrow vigorously, but also serve as a sturdy platform for bone regeneration in a desired, custom shape.

Materials used for craniofacial bone implants are either biologically inactive and extremely hard, like titanium, or biologically active and too soft, like biopolymers, said Roland Kaunas, associate professor in the Department of Biomedical Engineering. In our study, we have developed a synthetic polymer that is both bioactive and mechanically strong. These materials are also 3D printable, allowing custom-shaped craniofacial implants to be made that are both aesthetically pleasing and functional.

A detailed report on the findings was published online in the journalAdvanced Healthcare Materialsin March.

Each year, about 200,000 injuries occur to bones of the jaw, face and head. For repair, physicians often hold these broken bones in place using titanium plates and screws so that surrounding bone cells can grow and form a cover around the metal implant. Despite its overall success in aiding bone repair, one of the major drawbacks of titanium is that it does not always integrate into bone tissue, which can then cause the implant to fail, requiring another surgery in advanced cases.

Thus, biocompatible polymers, particularly a type called hydrogels, offer a preferable alternative to metal implants. These squishy materials can be loaded with bone stems cells and then 3D printed to any desired shape. Also, unlike titanium plates, the body can degrade hydrogels over time. However, hydrogels also have a known weakness.

Although the pliability of hydrogel-based materials makes them good inks for 3D bioprinting, their softness compromises the mechanical integrity of the implant and the accuracy of printed parts, said Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering.

To increase the stiffness of the hydrogel, the researchers developed a nanoengineered ionic-covalent entanglement or NICE recipe containing just three main ingredients: an extract from seaweed called kappa carrageenan, gelatin and nanosilicate particles that both stimulate bone growth and mechanically reinforce the NICE hydrogel.

First, they uniformly mixed the gelatin and kappa carrageenan at microscopic scales and then added the nanosilicates. Gaharwar said the chemical bonds between these three items created a much stiffer hydrogel for 3D bioprinting with an almost eight-fold increase in strength compared to individual components of NICE bioink.

Next, they added adult stem cells to 3D parts printed with NICE ink and then chemically induced the stem cells to convert into bone cells. Within a couple of weeks, the researchers found that the cells had grown in numbers, producing high levels of bone-associated proteins, minerals and other molecules. In aggregate, these cell secretions formed a scaffold, known as an extracellular matrix, with a unique composition of biological materials needed for the growth and survival of developing bone cells.

When the scaffolds are fully developed, the researchers noted that the bone cells could be removed from the scaffold and the hydrogel-based implant can then be inserted into the site of skull injury where the surrounding, healthy bones initiate healing.Over time, the 3D printed scaffolds biodegrade, leaving behind a healed bone in the right shape.

The idea is to have the bodys own bone repair machinery participate in the repair process, Kaunas said. Our biomaterial is enriched with this regenerative extracellular matrix, providing a fertile environment to naturally trigger bone and tissue restoration.

The researchers said that the 3D-printed scaffolds provide a strong structural framework that facilitates the attachment and growth of healthy bone cells. Also, they found that developing bone cells penetrate through the synthetic material, thereby increasing the functionality of the implant.

Although our current work is focused on repairing skull bones, in the near future, we would like to expand this technology for not just craniomaxillofacial defects but also bone regeneration in cases of spinal fusions and other injuries, Kaunas said.

Other contributors to this study include Candice Sears, Eli Mondragon, Zachary Richards, Nick Sears and David Chimene from the Texas A&M Department of Biomedical Engineering; and Eoin McNeill and Carl A. Gregory from the Texas A&M Health Science Center.

This research is funded by the National Institutes of Health and the National Science Foundation.

The rest is here:
Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts - Texas A&M University Today